Skip to main content

Table 3 Association of IVIG treatment with mortality among sub-groups

From: Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study

Sub-groups sHR (95% confidence interval) P value
PaO2/FiO2 ratio   
> 100 mm Hg 3.44 (2.04–5.78)  < 0.001
≤ 100 mm Hg 2.17 (1.07–4.41) 0.03
Serum ferritin level   
< 1000 mcg/L 3.45 (1.87–6.38)  < 0.001
≥ 1000 mcg/L 2.79 (1.52–5.11) 0.001
Time from ICU admission to IVIG therapy   
< 5 days 2.65 (1.07–6.56) 0.035
≥ 5 days 3.89 (1.85–8.18)  < 0.001
Number of IVIG doses received   
≤ 3 doses 3.72 (1.39–9.91) 0.009
> 3 doses 3.42 (1.69–6.93) 0.001
  1. IVIG, intravenous immunoglobulin; sHR, sub-distribution hazard ratio; PaO2/FiO2 ratio, ratio of partial pressure arterial oxygen and fraction of inspired oxygen; mcg/L, microgram per liter